{"asset":{"id":"c0a95c69-09a6-4fce-8015-e5af78f7a8b1","symbol":"AMGN","name":"Amgen","asset_type":"stock","exchange":"US","country":"US","currency":"USD","sector":"Health Care","industry":"Biotechnology","crypto_category":null,"coingecko_id":null,"is_active":true,"created_at":"2026-11-16T20:38:59.474331+00:00","updated_at":"2026-11-16T20:38:59.474331+00:00"},"latest_value_score":{"id":40,"asset_id":"c0a95c69-09a6-4fce-8015-e5af78f7a8b1","score_date":"2026-11-18","value_score":33.32930905714286,"value_component":33.32930905714286,"quality_component":89.16666666666667,"risk_component":46.975,"valuation_status":"weak","quality_status":"strong","risk_status":"neutral","value_trap_flag":false,"margin_of_safety":null,"fair_value_low":null,"fair_value_mid":null,"fair_value_high":null,"score_breakdown":{"risk":{"leverage_score":0.0,"liquidity_score":0.5658333333333334,"volatility_score":1.0},"value":{"pb_score":0.0,"pe_score":0.33813332000000007,"dividend_score":1.0,"ev_ebitda_score":0.2597857142857143},"quality":{"roe_score":1.0,"growth_score":0.5666666666666668,"margin_score":1.0},"raw_metrics":{"beta":0.417,"ev_ebitda":16.363,"forward_pe":18.260271,"net_margin":0.24139999,"trailing_pe":26.546667,"current_ratio":1.479,"price_to_book":17.258234,"debt_to_equity":376.303,"dividend_yield":2.18,"revenue_growth":0.085,"operating_margin":0.34120998,"return_on_equity":0.78353}},"created_at":"2026-11-18T08:00:50.992704+00:00"},"latest_ranking":{"id":"f7d6daaf-e101-44d4-b123-24b4d2744c41","asset_id":"c0a95c69-09a6-4fce-8015-e5af78f7a8b1","ranking_date":"2026-11-18","overall_score":60.37420938380953,"value_component":33.32930905714286,"quality_component":89.16666666666667,"risk_component":53.025,"technical_component":71.9,"news_component":57.5,"opportunity_type":"watchlist","rank":27,"rationale":{"news_bias":0.2884615384615384,"technical":"Signal: add, confidence: 53.0","asset_type":"stock","components":{"news_component":57.5,"risk_component":53.025,"value_component":33.32930905714286,"quality_component":89.16666666666667,"technical_component":71.9,"value_trap_penalty_applied":false},"news_strength":0.5200000000000001,"value_trap_flag":false,"articles_analyzed":10},"created_at":"2026-11-18T08:06:17.670692+00:00","updated_at":"2026-11-18T08:06:17.670692+00:00"},"latest_signal":{"id":"496f8ab6-bee3-46c9-b7b3-e3fac7af3b85","asset_id":"c0a95c69-09a6-4fce-8015-e5af78f7a8b1","signal_date":"2026-11-18T07:56:27.558316+00:00","signal_type":"tactical","action":"add","confidence":53.0,"entry_price":457.92999267578125,"entry_zone_low":445.470711844308,"entry_zone_high":470.3892735072545,"stop_loss":433.0114310128348,"target_1":482.8485543387277,"target_2":495.30783517020086,"risk_reward_ratio":1.0,"position_size_pct":2.0,"time_horizon":"days_to_weeks","invalidation_level":433.0114310128348,"summary":"Fused signal based on technical setup and 10 recent news articles. News bias: 0.29, news strength: 0.52.","status":"active","created_at":"2026-11-18T07:06:29.961874+00:00","updated_at":"2026-11-18T07:56:27.558355+00:00","engine_version":null,"price_as_of":null,"price_fetched_at":null,"price_basis":null,"reference_price":null,"technical_score":null,"calculation_metadata":null},"signal_reasons":[{"id":59,"signal_id":"496f8ab6-bee3-46c9-b7b3-e3fac7af3b85","category":"news","reason":"Positive recent news supports the existing technical setup | Moderate news impact detected | Technical confidence: 50.00 | News bias: 0.29 | News strength: 0.52 | Fused confidence: 53.00 | Recent articles analyzed: 10 | Previous technical action: hold","impact":"positive","weight":1.0,"source":"Finnhub news ingestion; 10 articles analyzed","created_at":"2026-11-18T07:56:27.872189+00:00"}],"recent_news":[{"id":262,"asset_id":"c0a95c69-09a6-4fce-8015-e5af78f7a8b1","published_at":"2026-11-17T17:00:00+00:00","title":"Biotechnology Market Companies 2027 Analysis: Amgen, Gilead, Regeneron, Vertex and Moderna Post Strong 2026 Results as Billion-Dollar Deals Reshape a Market Headed for USD 6.34 Trillion by 2035","url":"https://finnhub.io/api/news?id=7cc14baa024674eab6a4db0c98f5ac483e587145f710fd118d4c0982e814d166","source":"Yahoo","category":"company_news","sentiment":0.6666666666666666,"impact_score":2,"relevance_score":1.0,"summary":"Regeneron Grows 36%, Gilead Spends About USD 12.7 Billion on Four Deals and Pharma Buyers Race to Refill Pipelines: Precedence Research Company Intelligence on Leaders, Investments and DevelopmentsOttawa, Nov. 17, 2026 (GLOBE NEWSWIRE) -- The global biotechnology market is valued at USD 2.02 trillion in 2026 and is projected to reach USD 6.34 trillion by 2035 at a CAGR of 13.61%. Leading biotech companies raised their 2026 outlooks after third-quarter results, while large drugmakers announced ac","created_at":"2026-11-18T07:12:43.224571+00:00"},{"id":263,"asset_id":"c0a95c69-09a6-4fce-8015-e5af78f7a8b1","published_at":"2026-11-17T16:13:44+00:00","title":"Can Regeneron Stock Hit $1,400?","url":"https://finnhub.io/api/news?id=47caeb09c3274548716f38b0f3b71837d3a307862c4d2e0438f7c2089bbf240f","source":"Yahoo","category":"company_news","sentiment":0.0,"impact_score":0,"relevance_score":1.0,"summary":"Today's big story: Could Nvidia Stock Fall 50%? Follow The Cash.","created_at":"2026-11-18T07:12:43.340768+00:00"},{"id":264,"asset_id":"c0a95c69-09a6-4fce-8015-e5af78f7a8b1","published_at":"2026-11-17T13:05:02+00:00","title":"What iShares Biotechnology ETF (IBB) Bought: Gilead Leads on Nov. 13","url":"https://finnhub.io/api/news?id=17449836f3ef3db017ba6a7a32fac137804fd440c93334567fa8f844c430084d","source":"Yahoo","category":"company_news","sentiment":0.0,"impact_score":0,"relevance_score":1.0,"summary":"The fund added $84.9 million in new buying across 232 positions, led by $7.7 million of Gilead Sciences.","created_at":"2026-11-18T07:12:43.450025+00:00"},{"id":265,"asset_id":"c0a95c69-09a6-4fce-8015-e5af78f7a8b1","published_at":"2026-11-17T12:38:59+00:00","title":"Was Eli Lilly Stock's 45% Run Visible Early?","url":"https://finnhub.io/api/news?id=de89f1cac9fc116a4d679358a59ccba0c70b9053f66adf1d8306b55b3d4b662f","source":"Yahoo","category":"company_news","sentiment":0.0,"impact_score":0,"relevance_score":1.0,"summary":"Today's big story: Could Nvidia Stock Fall 50%? Follow The Cash.","created_at":"2026-11-18T07:12:43.560132+00:00"},{"id":266,"asset_id":"c0a95c69-09a6-4fce-8015-e5af78f7a8b1","published_at":"2026-11-16T23:12:32+00:00","title":"Amgen (AMGN) Just Gave Investors Something To Think About","url":"https://finnhub.io/api/news?id=681c38c8cca3d71e2036ab9eef2fac1c857ea37eb9cee2923a7630bbbf416479","source":"Yahoo","category":"company_news","sentiment":0.0,"impact_score":0,"relevance_score":1.0,"summary":"Amgen (AMGN) has just published detailed Phase 3 data for dazodalibep in Sjögren's disease, giving investors fresh clinical context for a stock that has climbed about 42% year to date. That clinical backdrop lands on a stock that has already been on a strong run. Amgen’s share price return is up 42.1% year to date and about 7.7% over the past month. In addition, the 5-year total shareholder return of 166.1% points to long-haul gains as momentum has recently strengthened. Scan how Amgen’s...","created_at":"2026-11-18T07:12:43.666567+00:00"},{"id":267,"asset_id":"c0a95c69-09a6-4fce-8015-e5af78f7a8b1","published_at":"2026-11-16T22:36:40+00:00","title":"The Winners Inside SCHD - November 2026","url":"https://finnhub.io/api/news?id=c073735c337135254275f5275d9ff4c0cb3f56e0208a335369f819a0db8f5c97","source":"SeekingAlpha","category":"company_news","sentiment":0.0,"impact_score":0,"relevance_score":1.0,"summary":"The bull case for SCHD: 34 holdings screen at least 10% undervalued, with expected long-term returns above 10%; its YTD lead over SPY tops 20%.","created_at":"2026-11-18T07:12:43.773607+00:00"},{"id":268,"asset_id":"c0a95c69-09a6-4fce-8015-e5af78f7a8b1","published_at":"2026-11-16T21:46:03+00:00","title":"Should You Trim Or Add To Your Viking Therapeutics Position?","url":"https://finnhub.io/api/news?id=9efa0185f1fa56f37424709066efd2f687389bf2455a466c27656c4199776a46","source":"Yahoo","category":"company_news","sentiment":0.0,"impact_score":0,"relevance_score":1.0,"summary":"For questions about this article or underlying research, email help@trefis.com.","created_at":"2026-11-18T07:12:43.881339+00:00"},{"id":269,"asset_id":"c0a95c69-09a6-4fce-8015-e5af78f7a8b1","published_at":"2026-11-16T19:59:32+00:00","title":"Dow Jones Biotech Giant Amgen In Buy Zone Amid Ongoing Stock Market Weakness","url":"https://finnhub.io/api/news?id=3b54b75a63911b63253d7ea7c89573440fd9f5d6e76eae20c42555f2aaca7069","source":"Yahoo","category":"company_news","sentiment":0.0,"impact_score":0,"relevance_score":1.0,"summary":"Dow Jones biotech giant Amgen stock is trading in a buy zone following its recent breakout move amid the ongoing market weakness.","created_at":"2026-11-18T07:12:43.988699+00:00"},{"id":270,"asset_id":"c0a95c69-09a6-4fce-8015-e5af78f7a8b1","published_at":"2026-11-16T18:06:31+00:00","title":"Novo Nordisk vs. Amgen: 1 Has the Blockbuster Weight-Loss Drugs, the Other Has a Promising Rival","url":"https://finnhub.io/api/news?id=e4fab600fe8d7e12f7eebeca7f6c68202afd71739d0b829991eb7eea829e1b72","source":"Yahoo","category":"company_news","sentiment":-0.3333333333333333,"impact_score":1,"relevance_score":1.0,"summary":"Novo Nordisk has the blockbuster weight-loss drugs, but Amgen could become a serious contender with its next-generation obesity treatment.","created_at":"2026-11-18T07:12:44.091229+00:00"},{"id":271,"asset_id":"c0a95c69-09a6-4fce-8015-e5af78f7a8b1","published_at":"2026-11-16T18:02:00+00:00","title":"AstraZeneca Secures US, EU Nod for New Myasthenia Gravis Drug Klygefa","url":"https://finnhub.io/api/news?id=3a8c82c2f8f328565fbca5cbaad1fcb3fca6fcbf8ab39ca6a469a5db1e6ae541","source":"Yahoo","category":"regulatory","sentiment":0.3333333333333333,"impact_score":1,"relevance_score":1.0,"summary":"AZN secures US and EU approval for Klygefa, a once-weekly gMG treatment that offers patients greater convenience.","created_at":"2026-11-18T07:12:44.193233+00:00"}]}